<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/15/278u" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/15/278u/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/15/278u/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_278u"><akn:num>278u</akn:num><akn:heading>Xylazine detection and analysis</akn:heading><akn:content><akn:p>§ 278u. Xylazine detection and analysis(a) DefinitionsIn this section:(1) DirectorThe term “Director” means the Director of the National Institute of Standards and Technology.


(2) Federal laboratoryThe term “Federal laboratory” has the meaning given such term in section 3703 of this title.


(3) InstituteThe term “Institute” means the National Institute of Standards and Technology.


(4) Institution of higher educationThe term “institution of higher education” has the meaning given such term in section 1001 of title 20.


(5) Nonprofit organizationThe term “nonprofit organization” means an organization described in section 501(c)(3) of title 26 and exempt from tax under section 501(a) of such title.


(6) XylazineThe term “xylazine” means the nonopioid tranquilizer methyl benzene compound frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.



(b) In generalThe Director shall—(1) support intramural basic measurement science and research of the Institute to advance—(A) analytical methods to identify, understand, differentiate, and categorize substances containing xylazine, novel synthetic opioids, or other new psychoactive substances;

(B) measurement technologies to shorten analysis timelines and enhance narcotic and opioid detection and analysis capabilities;

(C) new data tools, techniques, and processes to identify and publicly disclose relevant information concerning substances containing xylazine, novel synthetic opioids, or other new psychoactive substances; and

(D) such other areas as the Director determines to be critical to the development and deployment of technologies to measure and analyze the presence of xylazine, novel synthetic opioids, and other new psychoactive substances;


(2) support activities to inform and expand the development of near-real time spectrometry capabilities regarding xylazine, novel synthetic opioids, and other new psychoactive substances;

(3) convene and consult with</akn:p></akn:content><akn:subsection eId="subsec_278u_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_278u_b"><akn:num>(b)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(b) In general The Director shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_278u_c"><akn:num>(c)</akn:num><akn:heading>Controls</akn:heading><akn:content><akn:p>(c) Controls In carrying out activities under this section, the Director shall ensure proper security controls are implemented to protect sensitive information, as the Director considers appropriate and consistent with applicable provisions of law.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_278u_d"><akn:num>(d)</akn:num><akn:heading>Report</akn:heading><akn:content><akn:p>(d) Report Not later than 1 year after December 19, 2023, the Director shall submit to the Committee on Commerce, Science, and Transportation of the Senate and the Committee on Science, Space, and Technology of the House of Representatives a report on the implementation of this section. Such report may include recommendations for legislative action to improve the ability of the Director to carry out this section.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>